/GRNA
GRNA Stock - GreenLight Biosciences Holdings
Healthcare|BiotechnologyNASDAQ
$0.30-0.03%
$0.00 (-0.03%) • Jul 21
67
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.40
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.62
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+3572.8%upside
Target: $11.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for GRNA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.30 – $0.30
TARGET (TP)$11.00
STOP LOSS$0.28
RISK/REWARD1:548.7
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.44
52W High$5.90
52W Low$0.18
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|
| Revenue | $6.38M | N/A | $962,000 | $3.00M |
| Gross Profit | $6.38M | N/A | $962,000 | $3.00M |
| Gross Margin | 100.0% | N/A | 100.0% | 100.0% |
| Operating Income | $-163,919,000 | $-108,558,000 | $-52,284,000 | $-29,202,000 |
| Net Income | $-167,055,000 | $-114,729,000 | $-54,279,000 | $-28,966,000 |
| Net Margin | -2616.8% | N/A | -5642.3% | -965.2% |
| EPS | $-1.27 | $-0.93 | $-0.56 | $-0.30 |
Company Overview
GreenLight Biosciences Holdings, a biotechnology company, manufactures and sells ribonucleic acid (RNA) products for human health and agriculture applications. Its products for human health include mRNA vaccines and therapeutics; and agricultural RNA products to protect honeybees and crops. The company was founded in 2008 and is headquartered in Medford, Massachusetts.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
2
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
2 Bullish0 Neutral/Bearish
Price Targets
$5
Average Target
↑ 1486.0% Upside
Now
$4
Low
$5
Average
$6
High
Based on 2 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 8th 2022 | Canaccord Genuity | Initiation | Buy | $4 |
| October 14th 2022 | Credit Suisse | Initiation | Outperform | $5.5 |
Earnings History & Surprises
GRNABeat Rate
33%
Last 3 quarters
Avg Surprise
-75.7%
EPS vs Estimate
Beats / Misses
1/2
Last 12 quarters
Latest EPS
$-0.19
Q2 2023
EPS Surprise History
Q2 21
No data
Q3 21
No data
Q4 21
No data
Q1 22
No data
Q3 22
No data
Q4 22
+3.6%
$-0.27vs$-0.28
Q1 23
-204.0%
$-0.26vs$0.25
Q2 23
-26.7%
$-0.19vs$-0.15
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2024 | May 9, 2024 | — | — | — | — |
Q1 2024 | Mar 26, 2024 | — | — | — | — |
Q4 2023 | Nov 7, 2023 | — | — | — | — |
Q3 2023 | Aug 14, 2023 | — | — | — | — |
Q2 2023 | May 11, 2023 | $-0.15 | $-0.19 | -26.7% | ✗ MISS |
Q1 2023 | Mar 28, 2023 | $0.25 | $-0.26 | -204.0% | ✗ MISS |
Q4 2022 | Nov 9, 2022 | $-0.28 | $-0.27 | +3.6% | ✓ BEAT |
Q3 2022 | Sep 26, 2022 | — | $-0.42 | — | — |
Q1 2022 | Mar 31, 2022 | — | $-0.34 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-0.23 | — | — |
Q3 2021 | Sep 30, 2021 | — | $-0.30 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.28 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-0.22 | — | — |
Q4 2020 | Dec 31, 2020 | — | $-0.14 | — | — |
Latest News
Loading news...
Frequently Asked Questions about GRNA
What is GRNA's current stock price?
GreenLight Biosciences Holdings (GRNA) is currently trading at $0.30 per share. The stock has moved -0.03% today.
What is the analyst price target for GRNA?
The average analyst price target for GRNA is $11.00, based on 1 analyst.
What sector is GreenLight Biosciences Holdings in?
GreenLight Biosciences Holdings operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is GRNA's market cap?
GreenLight Biosciences Holdings has a market capitalization of $0.05 billion, making it a small-cap company.
Does GRNA pay dividends?
No, GreenLight Biosciences Holdings does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorALVR
AlloVir, Inc.
$9.81
Mkt Cap: $0.0B
BLUE
bluebird bio, Inc.
$4.97
Mkt Cap: $0.0B
ERYP
ERYTECH Pharma S.A.
$0.78
Mkt Cap: $0.0B
LIANY
LianBio
$0.11
Mkt Cap: $0.0B
MGTA
Magenta Therapeutics, Inc.
$0.70
Mkt Cap: $0.0B
PSTI
Pluristem Therapeutics Inc.
$1.00
Mkt Cap: $0.0B
RENB
Lunai Bioworks Inc.
$1.42
Mkt Cap: $0.0B
RNTX
Rein Therapeutics Inc.
$1.42
Mkt Cap: $0.0B
STSA
Satsuma Pharmaceuticals, Inc.
$1.10
Mkt Cap: $0.0B
SYRE
Spyre Therapeutics, Inc.
$33.40
Mkt Cap: $2.0B
Explore stocks similar to GRNA for comparison